# Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy

> **NCT03135977** · PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 36 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer
- Lung Cancer

## Interventions

- **DRUG:** Apatinib, Etoposide

## Key facts

- **NCT ID:** NCT03135977
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03135977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03135977, "Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03135977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*